Pérez Encinas M, Bello J L, Bendaña A, Rabuñal M J, González S, Abuín I, Noya M, Cadarso C
Servicio de Hematología y Hemoterapia, Hospital General de Galicia, Santiago de Compostela.
Med Clin (Barc). 1998 Jul 11;111(5):161-7.
Patients with non-Hodgkin's lymphoma (NHL) have increased serum levels of soluble interleukin-2 receptor (sCD25). In this study the authors investigate: a) the value of sCD25, compared to other serum markers, as tumor marker, and b) the relationship of the sCD25 with the response to therapy and prognosis.
Serum interleukin-2 receptor (sCD25) levels were measured at diagnosis in 63 patients with NHL (low-grade lymphoma 30 and high-grade lymphoma 33).
High levels of sCD25 were found in these patients compared to a control group (median 1,757 U/ml vs 385 U/ml; p < 0.0001). Significant differences were also found between the high-grade group and the low-grade group, as a whole and within the same Ann Arbor stage. sCD25 showed a correlation coefficient higher than other serum parameters (albumin, LDH, beta 2-microglobulin, uric acid, C-reactive protein) with Ann Arbor stage and with the number of involved lymph nodes or extralymphatic organs. In the high-grade NHL, the median of sCD25 (3,000 U/ml) separates patients with differences in the overall survival (p = 0.0138) and in percentage of complete remisions (p = 0.0079). All the patients with sCD25 < or = 3,000 U/ml reached the remision. The association sCD25 > 3,000 U/ml and albumin < 3.5 g/dl selected to 5 out of 6 patients who failed induction chemotherapy, and only 2 out of 22 who reached the remision.
The sCD25 is the best serum factor for estimating tumor burden in NHL. sCD25 level isolates or associated with albumin provides prognostic information.
非霍奇金淋巴瘤（NHL）患者血清可溶性白细胞介素-2受体（sCD25）水平升高。在本研究中，作者调查了：a）与其他血清标志物相比，sCD25作为肿瘤标志物的价值；b）sCD25与治疗反应和预后的关系。
对63例NHL患者（30例低度淋巴瘤和33例高度淋巴瘤）在诊断时测定血清白细胞介素-2受体（sCD25）水平。
与对照组相比，这些患者的sCD25水平较高（中位数1757 U/ml对385 U/ml；p<0.0001）。在整体以及相同Ann Arbor分期的高度组和低度组之间也发现了显著差异。sCD25与Ann Arbor分期以及受累淋巴结或结外器官数量的相关系数高于其他血清参数（白蛋白、乳酸脱氢酶、β2-微球蛋白、尿酸、C反应蛋白）。在高度NHL中，sCD25的中位数（3000 U/ml）区分出总生存期（p = 0.0138）和完全缓解率（p = 0.0079）存在差异的患者。所有sCD25≤3000 U/ml的患者均达到缓解。sCD25>3000 U/ml与白蛋白<3.5 g/dl的联合，在6例诱导化疗失败的患者中选择出5例，而在22例达到缓解的患者中仅选择出2例。
sCD25是评估NHL肿瘤负荷的最佳血清因子。sCD25水平单独或与白蛋白相关可提供预后信息。
